Novartis Sp ADR (NVS)
$108.24
0.68 (0.63%)
NVS Stock Quote Delayed 30 Minutes
How to Pick the Best High-Yield Stocks in Big Pharma
Big Pharma is a great place to find yield, and health care is a sure-fire long-term bet. But rather than shake a stick at this sector, go ahead ... be picky.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$108.02
Market Cap
215.13B
PE Ratio
18.44
EPS
5.87
Volume (Avg. Vol.)
1.84M
Day's Range
$107.51 - $109.04
52-Week Range
$92.35 - $120.92
Dividend & Yield
$3.74 (3.45%)
NVS Stock Predictions, Articles, and Novartis Sp ADR News
4 Sick Healthcare Stocks to Sell
Healthcare stocks are subject to patent problems and pricing pressures on contracts. Not everyone is doing well, and these 4 stocks are a sell
Pfizer is Still a Pharmaceutical-Giant Buy
Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio.
Feel Safe Scooping Up Swiss Stocks
There's a lot to like about Switzerland as an investment haven. It's not a perfect environment, but a number of Swiss stocks look promising right now.
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.
Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World
Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.
Investors Bid Up Homebuilders, Energy Stocks — Monday’s IP Market Recap
A rise in pending home sales lifts equities to a flat day overall. Lowe's joins the homebuilders' rise for the day.
5 Signs Unemployment Will Rise Again Soon
A steady drumbeat of large-scale layoffs and cutbacks could eventually cast a shadow over the recent 8.3% headline jobless rate.
‘Spam’ Linked to Diabetes in Native Americans
A new study raises questions about processed meat intake among Native Americans living on reservations and the development of diabetes.
Amylin Gets a Boost From Its Diabetes Drug Approval
FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.
If Novartis’ MS Drug Falters, Biogen Will Gain
After the deaths of 11 people who were taking the drug, concerns that Gilenya may cause heart problems has hit NVS hard, ending the stock's months-long upswing.
J.C. Penney to Cut Thousands of Jobs
A New York Post report says the struggling retailer will cut thousands of jobs, hitting most of the retailer's 1,200 locations.
Are Pharma’s ‘Good Old Days’ Gone Forever?
You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry.
Novartis Cutting 2,000 Jobs – So Much for Healthy Healthcare Stocks!
Novartis NYSE:NVS is cutting nearly 2,000 jobs in the United States. The reason? Patent expiration for its blockbuster blood pressure drug Diovan.
Teva’s New CEO Is Battle-Tested. Good Thing
Drug industry vet Jeremy Levin earned his stripes making deals for Bristol-Myers Squibb, but he'll face tough going at the generic-drug maker.
Does It Still Make Sense to Diversify Internationally?
Yes, but you'll have to do so prudently and with patience. Overseas markets do offer opportunities for careful investors.
10 Best 401(k) Plans in America
The rankings are in. These 10 big employers offer the best 401(k) plans in the nation. See if your company made the list.
7 Safe Overseas Dividend Plays
Here's how to safely get some international diversification and dividend yield.
RIMM Completes a Week of Gloomy Outlooks — Friday’s IP Market Recap
Research In Motion joined Intel, Best Buy and First Solar in forecasting leaner times ahead. Here's a look at RIM, as well as other big news from this week.
Covidien Follows Abbott With a Pharma Spin-Off
Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?
Taiwan: Almost Ready for Prime Time!
Taiwan is a growing force in electronics and tech, as well as a foreign-business friendly country. These two ETFs can help aggressive investors take the reins.
